ED50, or median effective dose, is the dose of a drug that produces a desired therapeutic effect in 50% of the people who take it. It’s one of the most fundamental measurements in pharmacology, used to compare drug potency, establish safe dosing ranges, and guide the development of new medications.
What the “50” Actually Means
The number refers to a population threshold, not a percentage of effect in one person. If you give a specific dose of a painkiller to 100 people, and 50 of them experience adequate pain relief, that dose is the ED50. The other 50 people might need a higher dose to get the same result, or they might respond partially. The ED50 captures the point where half the population crosses the line into a meaningful response.
This makes ED50 a statistical measure. No single patient “has” an ED50. It describes how a drug performs across a group, which is why it’s so useful for standardizing drug comparisons and setting recommended starting doses. In practice, your doctor uses the published ED50 as a starting point and adjusts based on how you respond individually.
How ED50 Relates to Potency
ED50 is the standard yardstick for drug potency. A drug with a lower ED50 is more potent because it takes less of it to produce the desired effect in half the population. If Drug A has an ED50 of 5 mg and Drug B has an ED50 of 50 mg for the same effect, Drug A is ten times more potent.
Potency and efficacy are not the same thing, though they’re often confused. Potency (measured by ED50) tells you how much drug you need. Efficacy tells you the maximum effect a drug can produce regardless of dose. A highly potent drug isn’t necessarily a better drug. It just means you need a smaller dose to get results. Two painkillers might both fully relieve a headache (equal efficacy), but one might do it at 200 mg while the other requires only 10 mg (different potency, different ED50 values).
Graded vs. Quantal Dose-Response
ED50 can be measured in two different ways depending on the question being asked. In a graded dose-response, you’re measuring how much of an effect a drug produces in an individual. The response exists on a spectrum: a little effect, moderate effect, maximum effect. Here, ED50 represents the dose that produces 50% of the maximum possible response. You might also see this written as EC50 (median effective concentration), which refers to drug concentration in the blood rather than the dose given.
In a quantal dose-response, the outcome is binary: either the patient responded or they didn’t. Did the seizure stop? Did the patient fall asleep? There’s no sliding scale. Here, ED50 is the dose at which 50% of patients achieve that yes-or-no outcome. Quantal measurements are more common in clinical settings because they map directly to questions doctors and patients care about.
The Dose-Response Curve
ED50 sits at the midpoint of a characteristic S-shaped (sigmoidal) curve. When researchers plot increasing doses along the horizontal axis and the percentage of people responding along the vertical axis, the resulting curve starts flat at low doses where almost nobody responds, rises steeply through the middle range, and flattens again at high doses where nearly everyone responds. The ED50 falls right at the inflection point, where the curve is steepest and the response is halfway between baseline and maximum.
This curve shape matters because it tells researchers about the drug’s behavior. A steep curve means there’s a narrow dose range between “barely works” and “works for almost everyone.” A shallow curve means the effective dose varies widely across the population. Both of these features influence how a drug is prescribed and how much room there is for dosing adjustments.
Why ED50 Matters for Drug Safety
ED50 becomes especially important when paired with two related values: TD50 (the dose that causes toxic effects in 50% of the population) and LD50 (the dose that’s lethal to 50% of a test population, measured only in animal studies). The ratio between these numbers determines how safe a drug is to use.
The therapeutic index is calculated by dividing the toxic dose (TD50) by the effective dose (ED50). A drug with a therapeutic index of 100 has a wide safety margin: the toxic dose is 100 times higher than the effective dose. A drug with a therapeutic index of 2 has a dangerously narrow margin, meaning the dose that helps is uncomfortably close to the dose that harms. Drugs with low therapeutic indices, like blood thinners and certain heart medications, require careful monitoring and precise dosing.
How ED50 Is Used in Drug Development
During drug development, researchers rely heavily on ED50 to compare candidate compounds and decide which ones to advance. If two experimental drugs target the same disease, the one with the lower ED50 (higher potency) may be preferred, all else being equal, because lower doses generally mean fewer side effects and simpler dosing schedules. In one published example from lead optimization research, a promising compound had an ED50 of 1.8 μmol/L, while a simplified version of the same molecule retained useful activity at an ED50 of 9.9 μmol/L. That fivefold difference helps researchers weigh potency against manufacturing ease and cost.
The FDA requires dose-response data as a core component of drug registration. Their guidance specifies that trials should test at least three dose levels, use randomization and blinding, and cover as wide a dose range as safely possible. The goal is to map the full dose-response relationship rather than simply proving a single dose works better than placebo. This is where ED50 becomes practical: it anchors the recommended starting dose that eventually appears on the drug’s label.
Why Individual Responses Vary
ED50 describes a population average, but individual patients can fall far from that average. Age, weight, kidney and liver function, and other medications all influence how much drug you actually need. Genetics may be the biggest factor of all. Research suggests that genetic variants can account for up to 95% of the differences in how individuals respond to certain drugs.
Blood thinners are a well-known example. Patients who metabolize the drug slowly face a much higher risk of internal bleeding at standard doses. Dosing algorithms that incorporate genetic testing alongside clinical factors can significantly improve safety. This is the frontier of personalized medicine: moving beyond population averages like ED50 toward doses tailored to your specific biology. For now, though, ED50 remains the foundation that those personalized adjustments are built on.